Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02007200 · OUTCOME

The Number of Participants Alive Without Relapse at Last Follow-up

Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery · Source last updated 2016-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to 24 months

What was measured

Relapse-free survival will be determined at the last follow-up visit.

Analysis population: 55 patients were enrolled. 3 patients did not undergo treatment. 13 patients had insufficient tissue and were therefore not evaluable. Only the 39 evaluable patients were included in the analysis.

Groups in this outcome

Treatment (Soy Isoflavones)

Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Soy Isoflavones)39

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Soy Isoflavones)24Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        24
denoms
  1. counts
    1. group Id
      OG000
      value
      39
    units
    Participants
description
Relapse-free survival will be determined at the last follow-up visit.
groups
  1. description
    Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
    id
    OG000
    title
    Treatment (Soy Isoflavones)
param Type
NUMBER
population Description
55 patients were enrolled. 3 patients did not undergo treatment. 13 patients had insufficient tissue and were therefore not evaluable. Only the 39 evaluable patients were included in the analysis.
reporting Status
POSTED
time Frame
Up to 24 months
title
The Number of Participants Alive Without Relapse at Last Follow-up
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice